Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...

Nvidia sold its entire 7.71 million share stake in Recursion Pharmaceuticals by December 31, 2025 Recursion stock swung 14% lower intraday Wednesday before closing 2% higher ARK Invest bought 1.25 ...

The co-founders of startup Ricursive Intelligence seemed destined to be co-founders. Anna Goldie, CEO, and Azalia Mirhoseini, CTO, are so well-known in the AI community that they were among those AI ...

How must databases adapt to generative AI, and how should databases be integrated with large language models (LLMs)? These are questions that Sailesh Krishnamurthy has grappled with for several years ...

Human and Droid Competition at Office. Robotic Character Worker Future Evolution. Future historians will see that the seeds of a profound transformation were planted in 2025. By 2050, most people will ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Every major technological wave raises the same question: what does this mean for jobs and work? History provides a useful lens. The steam engine industrialized muscle, pulling workers into centralized ...

In most enterprises, data access still feels like a locked room with SQL as the only key. Business teams depend on data engineers for every report, dashboard, or metric tweak. Even in the age of ...

As SQL development increasingly becomes part of full-stack workflows, developers are looking for ways to simplify their tooling without compromising capability. While SQL Server Management Studio ...

RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...